VN 2222

Drug Profile

VN 2222

Latest Information Update: 08 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vita
  • Class Antidepressants; Piperazines; Propanols
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 03 Sep 2004 Grupo Vita has been acquired by Procter & Gamble
  • 03 Sep 2004 Grupo Vita is now called Vita
  • 23 Apr 2003 A preclinical study has been added to the Affective disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top